Key Points
- United Therapeutics CFO James Edgemond sold 10,000 shares on April 9 at an average price of $577.89 for proceeds of $5,778,900, part of multiple recent 10,000-share sales executed under a pre-arranged Rule 10b5-1 plan that cut his ownership by 34.63% to 18,876 shares.
- United Therapeutics recently beat quarterly EPS estimates ($7.70 vs. $6.78) with revenue up 7.4% year-over-year, and analysts remain largely positive — a "Moderate Buy" consensus with an average price target of $601.50 while the stock trades around $571 and the company has a market cap near $25.1 billion.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $577.89, for a total value of $5,778,900.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company's stock, valued at $10,908,251.64. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Edgemond also recently made the following trade(s):
- On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total value of $5,584,000.00.
- On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.
- On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
- On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00.
- On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.
United Therapeutics Trading Down 0.5%
Shares of UTHR opened at $571.73 on Friday. The stock has a 50 day moving average of $516.68 and a 200 day moving average of $484.30. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $607.89. The company has a market capitalization of $25.06 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.65 and a beta of 0.75.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the prior year, the company earned $6.19 earnings per share. United Therapeutics's revenue was up 7.4% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Analysts Set New Price Targets
Several equities analysts have weighed in on UTHR shares. Bank of America increased their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a report on Tuesday, March 31st. UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Wells Fargo & Company increased their price objective on United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a report on Tuesday, March 31st. HC Wainwright increased their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Finally, Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research note on Thursday, March 12th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $601.50.
View Our Latest Analysis on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
Several large investors have recently added to or reduced their stakes in UTHR. Torren Management LLC bought a new stake in United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after buying an additional 56 shares during the period. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter valued at $31,000. Institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
